Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Turkey
Management Report
Published: January 2010
Pages: 50
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
TURKEY - MARKET REVIEW
Turkey accounts for around 40% the total Middle Eastern pharmaceutical market, due to its population of 73 million and large GDP. However, growth in the Turkish market may be slightly tempered by the government’s ongoing healthcare reforms, particularly in regards to price controls. GDP growth of an estimated 3.8% per annum between 2010 and 2015 will assist the growth of the pharmaceutical market; however, the legal environment will pose challenges. Patent legislation falls short of full TRIPS criteria, specifically Article 39, regarding the lack of pipeline protection and data protection legislation passed in 2005 provides little effective protection for products currently on the market, and limits protection for future products. With concerns about copyright piracy, trademark counterfeiting, IPR enforcement and delays for marketing approvals for generic pharmaceuticals, the USTR kept Turkey on its Priority Watch List. Turkey was upgraded to this list in 2004.
Turkey became an official EU candidate country in 1999 but was told that accession would be impossible without visible progress on human rights and economic reform. The country has since abolished the death penalty, introduced tougher measures against torture and implemented other reforms to the penal code. It has brought in significant civil and other rights reforms, especially in the areas of women's rights and Kurdish culture, language education and broadcasting. Talks on Turkey's accession to the EU officially opened in October 2005, but negotiations have been painfully slow due to failure to meet the preconditions of many of the acquis chapters and the country’s refusal to open its ports and airports to Greek Cypriot ships and aircraft. Turkey is not expected to become a member state until at least 2015. Turkey has sought to align its national legislation on pharmaceuticals with that of the EU, but the harmonisation process is still incomplete.
Turkey has a strong generics industry; according to the Pharmaceutical Manufacturers Association of Turkey, almost three quarters of locally produced pharmaceuticals were generics in 2008. Whilst generics account for a third of the market in value terms and over 50% in volume terms, there is room for this sector to expand as physicians are not actively encouraged to prescribe generic drugs and there are no incentives for pharmacists to dispense them. Generic substitution is legal in Turkey; the pharmacist is obliged to inform the patient of the substitution, but this may be declined.
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
TURKEY - MARKET REVIEW
Turkey accounts for around 40% the total Middle Eastern pharmaceutical market, due to its population of 73 million and large GDP. However, growth in the Turkish market may be slightly tempered by the government’s ongoing healthcare reforms, particularly in regards to price controls. GDP growth of an estimated 3.8% per annum between 2010 and 2015 will assist the growth of the pharmaceutical market; however, the legal environment will pose challenges. Patent legislation falls short of full TRIPS criteria, specifically Article 39, regarding the lack of pipeline protection and data protection legislation passed in 2005 provides little effective protection for products currently on the market, and limits protection for future products. With concerns about copyright piracy, trademark counterfeiting, IPR enforcement and delays for marketing approvals for generic pharmaceuticals, the USTR kept Turkey on its Priority Watch List. Turkey was upgraded to this list in 2004.
Turkey became an official EU candidate country in 1999 but was told that accession would be impossible without visible progress on human rights and economic reform. The country has since abolished the death penalty, introduced tougher measures against torture and implemented other reforms to the penal code. It has brought in significant civil and other rights reforms, especially in the areas of women's rights and Kurdish culture, language education and broadcasting. Talks on Turkey's accession to the EU officially opened in October 2005, but negotiations have been painfully slow due to failure to meet the preconditions of many of the acquis chapters and the country’s refusal to open its ports and airports to Greek Cypriot ships and aircraft. Turkey is not expected to become a member state until at least 2015. Turkey has sought to align its national legislation on pharmaceuticals with that of the EU, but the harmonisation process is still incomplete.
Turkey has a strong generics industry; according to the Pharmaceutical Manufacturers Association of Turkey, almost three quarters of locally produced pharmaceuticals were generics in 2008. Whilst generics account for a third of the market in value terms and over 50% in volume terms, there is room for this sector to expand as physicians are not actively encouraged to prescribe generic drugs and there are no incentives for pharmacists to dispense them. Generic substitution is legal in Turkey; the pharmacist is obliged to inform the patient of the substitution, but this may be declined.